Cigna Corporation

(New York Stock Exchange)
Back to all articles
Bullish +65

UBS keeps USD 400.00 target for Cigna Group stock

Earnings report AI-generated analysis

πŸ“ˆ Cigna Group reported Q2 2026 revenue of USD 71.70 billion, beating the consensus estimate of USD 70.18 billion.

πŸ’° Adjusted earnings per share reached USD 7.78, surpassing the analyst forecast of USD 7.59.

🎯 UBS reiterated a Buy rating and maintained a USD 400.00 price target for Cigna Group stock.

πŸ“… Cigna reaffirmed its 2026 outlook with adjusted revenue guidance of approximately USD 280 billion.

πŸš€ The company committed to a USD 3.00 billion modernization and productivity initiative through 2030.

πŸ“Š Cigna's P/E ratio of 11.69 is significantly lower than peers UnitedHealth Group (21.56) and Elevance Health (18.90).

πŸ’΅ The stock carries a dividend yield of 2.00 percent with a market capitalization of USD 74.7 billion.

πŸ“‰ Cigna stock was trading at EUR 254.05, while the primary-exchange quote was USD 282.53.

Bullish Signals
  • Cigna Group beat Q2 2026 revenue expectations with USD 71.70 billion versus a consensus of USD 70.18 billion.
  • Adjusted earnings per share of USD 7.78 exceeded the forecast of USD 7.59, demonstrating strong profitability.
  • UBS maintained its Buy rating and USD 400.00 price target following the company's solid financial results.
  • Cigna reaffirmed full-year 2026 guidance with adjusted revenue of approximately USD 280 billion and EPS of at least USD 30.45.
  • The company announced a substantial USD 3.00 billion investment in a modernization and productivity initiative through 2030.
Full Analysis
Cigna Group reported second-quarter 2026 revenue of USD 71.70 billion, surpassing the consensus estimate of USD 70.18 billion. The company's adjusted earnings per share reached USD 7.78, exceeding the forecast of USD 7.59. This strong financial performance has reinforced UBS's Buy rating and maintained its price target at USD 400.00 for Cigna Group stock. Cigna reaffirmed its full-year 2026 outlook with adjusted revenue guidance of approximately USD 280 billion and adjusted earnings per share of at least USD 30.45. The company also highlighted a significant USD 3.00 billion modernization and productivity initiative planned through 2030 to drive future efficiency and growth. Valuation metrics show Cigna trading with a P/E ratio of 11.69, which is notably lower than peers UnitedHealth Group (P/E 21.56) and Elevance Health (P/E 18.90). The stock's market capitalization stands at USD 74.7 billion, reflecting investor interest in its undervalued multiple relative to the broader healthcare sector. The article notes that Cigna's current trading price in euros sits below its primary-exchange quote range, while maintaining a dividend yield of 2.00 percent. Analysts view the company's lower valuation as a potential opportunity given its solid revenue beat and clear strategic roadmap for productivity improvements.